Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation


28 Sep 2019


Poster Display session 1


Basic Science

Tumour Site


Chih-Yung Yang


Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238


C. Yang1, C. Lin2, J. Jiang3

Author affiliations

  • 1 Department Of Education And Research, Taipei City Hospital, 106 - Taipei/TW
  • 2 Institute Of Microbiiology And Immunology, National Yang-Ming University, 112 - Taipei/TW
  • 3 Colorectal Surgery, Taipei Veterans General Hospital, 11217 - Taipei City/TW


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1559


Colorectal cancer stem cells (CSCs) serve crucial functions in tumor relapse, metastasis and therapy failure. Interleukin 17 receptor A (IL-17RA) is a potent mediator in the pathogenesis and progression of colorectal cancer. Our previous study showed that IL-17RA could promote angiogenesis, tumor growth and metastasis. In addition, IL-17RA was correlated with CRC recurrence. Recent study showed IL-17RA play a potential role in self-renewal in glioma stem cells. This study aims to evaluate the functional role and mechanism of IL-17RA in colorectal CSCs.


In this study, IL-17RA stable overexpression cells were used to examine the change of sphere formation, proliferation, CSC markers and epithelial-mesenchymal transition biomarkers and the regulation mechanism of signaling pathway. The specific IL-17RA signaling inhibitors were used to evaluate the function of the IL-17RA signaling affecting the CSC markers, epithelial-mesenchymal transition gene expression and sphere formation.


We observed high IL-17RA expression can significantly promote the self-renewal by increasing stem cell markers CD133, ALDH1, Lgr5 and Sox2 expression and the ability to form tumorsphere in SW480 and SW620 cells. In additional, IL-17RA overexpression markedly increased chemoresistant ability and mesenchymal markers Vimentin, Slug, Snail, Zeb1expression. The STAT3 inhibitor remarkably decreased the CD133 stem cell gene, drug resistance and tumorsphere ability.


IL-17RA can enhance the self-renewal ability via activating the STAT3 pathway. Therefore, we expect that IL-17RA could serves as a prognosis marker and a potential therapeutic target in CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Chih-Yung Yang.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.